SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?


To: Icebrg who wrote (377)11/5/2003 8:19:26 PM
From: keokalani'nui  Respond to of 824
 
Thanks Erik.

It was a freakin' cure at last year's ASH! Where's the stinkin' pivotal P2/3? They've got the 12 month MN safety data already.

Maybe there are only 11 patients with PNH in the developed world and they are in this study.

Do I sound stressed with this investment??? Yer darn right!



To: Icebrg who wrote (377)11/11/2003 2:05:30 PM
From: Icebrg  Read Replies (2) | Respond to of 824
 
Eculizumab has been granted Orphan Drug Status by the European Commission.

Erik

emea.eu.int